Form 8-K - Current report:
SEC Accession No. 0001193125-24-095508
Filing Date
2024-04-15
Accepted
2024-04-15 07:30:34
Documents
16
Period of Report
2024-04-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d818381d8k.htm   iXBRL 8-K 28443
2 EX-10.1 d818381dex101.htm EX-10.1 9790
7 GRAPHIC g818381g87d27.jpg GRAPHIC 9938
  Complete submission text file 0001193125-24-095508.txt   224989

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mreo-20240415.xsd EX-101.SCH 3556
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mreo-20240415_def.xml EX-101.DEF 14947
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mreo-20240415_lab.xml EX-101.LAB 24641
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mreo-20240415_pre.xml EX-101.PRE 15915
19 EXTRACTED XBRL INSTANCE DOCUMENT d818381d8k_htm.xml XML 6137
Mailing Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF
Business Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF 4403330237300
Mereo BioPharma Group plc (Filer) CIK: 0001719714 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38452 | Film No.: 24843108
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)